Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Visualant, Inc. (VSUL) Granted 6th Patent For ChromaID™ Electromagnetic Technology

|Includes: Visualant, Inc. (VSUL)

Visualant, developer of disruptive light-based technologies, has received from the U.S. Office of Patents and Trademarks the company's sixth patent, entitled "Method, Apparatus and Article To Facilitate Distributed Evaluation of Object Using Electromagnetic Energy," on its ChromaID™ technology.

The new patent is in line with Visualant's goal to introduce efficient authentication, identification, and diagnostic methods into the marketplace. The news comes quick on the heels of the company's timely and strategic relationship with Intellectual Ventures, a company that collaborates with leading inventors, partners with pioneering companies, and invests both expertise and capital in the process of invention.

"We rigorously pursue strong protection for our intellectual property. We are very pleased to receive this, our sixth patent," Ron Erickson, Visualant Founder and CEO, stated in the news release. "…. We have more patents pending and expect more patents to be issued as we build the intellectual property foundation for Visualant's business and move into the marketplace with diverse applications of our ChromaID technology. This is a process we are accelerating through our new strategic relationship with Intellectual Ventures."

Devices embedded with the newly patented ChromaID technology can read and record natural chromatic markers by structuring light onto a substance, through a liquid or gas, or off a surface. Once scanned, the technology captures the reflected light and creates a unique ChromaID profile that can be matched against existing databases to identify, detect, or diagnosis markers invisible to the human eye.

For more information, visit

QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit